CD8A and neoplasm: Monomethoxy PEG-poly(lactic-co-glycolic acid) nanoparticles encapsulating the hypoxia-activated prodrug evofosfamide (TH-302), a 2-nitroimidazole derivative that releases bromo-isophosphoramide mustard, effectively ameliorated tumor hypoxia, reduced HIF-1α and PD-L1 expression, and facilitated infiltration of CD8+ T cells, thereby potentiating anti-PD-1 therapy[164].